Five Prime Therapeutics

Five Prime Therapeutics Newswire

Comprehensive Real-Time News Feed for Five Prime Therapeutics.

Results 1 - 20 of 97 in Five Prime Therapeutics

  1. Bellicum Leaps On Biotech IPO, Setting Stage For JunoRead the original story

    3 hrs ago | Investor's Business Daily

    Capping a big year for biotech IPOs, Bellicum Pharmaceuticals bolted on its public debut Thursday, with Juno Therapeutics pricing above estimates. raised $140 million after offering 7.35 million shares at 19 each, above its 15-17 expected range.

    Comment?

  2. Company seeks approval for skin cancer drugRead the original story w/Photo

    Monday Dec 15 | Fox News

    A Roche Holding AG subsidiary submitted a drug for treating people treating patients with an advanced form of skin cancer to U.S. regulators, the company said Monday, starting the process for potential approval of the therapy. Genentech, Roche's U.S.-based biotechnology subsidiary, said it had submitted a new drug application for its cobimetinib treatment to be used in combination with the existing Zelboraf treatment for patients with mutation-positive advanced melanoma.

    Comment?

  3. Changes In Roche Board Of Directors And Enlarged Corporate Executive CommitteeRead the original story

    Thursday Dec 11 | BioSpace

    At its December meeting, the Board of Directors of Roche Holding recommended first proposals for approval by the AGM, scheduled for 3 March 2015. All current members of the BoD will stand for re-election: The following will be nominated for election as new members of the Board of Directors: Bernard Poussot Professor Richard P. Lifton, Ph.D. Christoph Franz, Chairman of Roche said: a zI am delighted that we are able to propose two outstanding individuals to be elected as new members of the Board who will bring significant experience from their careers in the pharmaceutical industry and in biomedical research, respectively."

    Comment?

  4. Roche Names New Genentech ChiefRead the original story w/Photo

    Friday Dec 12 | Wall Street Journal

    Roche Holding AG said Friday it plans to expand its board of directors by two members, as it announced the head of its important Genentech research and development arm will retire. Basel-based Roche said it will nominate Bernard Poussot, the former chief executive of Wyeth Corp., and Richard Lifton, a genetics professor at Yale University's medical school to the board.

    Comment?

  5. Five Prime Therapeutics, Inc. Initiates Patient Dosing In Phase 1...Read the original story

    Thursday Dec 4 | BioSpace

    Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced that the company has initiated dosing in its Phase 1 clinical trial of FPA144, an anti-FGF receptor 2b antibody. FPA144 is designed to inhibit tumor growth by preventing the binding of certain fibroblast growth factors to FGF receptor 2b and directly kill tumor cells in a process called antibody-dependent cell-mediated cytotoxicity .

    Comment?

  6. Five Prime Therapeutics, Inc. To Present At The Oppenheimer 25th Annual Healthcare ConferenceRead the original story

    Thursday Dec 4 | BioSpace

    Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced that Lewis T. "Rusty" Williams, M.D., Ph.D., President and Chief Executive Officer of Five Prime, will present at the Oppenheimer 25th Annual Healthcare Conference on Wednesday, December 10 at 3:55 PM Eastern Time. The conference will take place at the Crowne Plaza Hotel in New York City.

    Comment?

  7. Five Prime Therapeutics to Present at the Oppenheimer 25th Annual Healthcare ConferenceRead the original story w/Photo

    Thursday Dec 4 | GlobeNewswire

    Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced that Lewis T. "Rusty" Williams, M.D., Ph.D., President and Chief Executive Officer of Five Prime, will present at the Oppenheimer 25th Annual Healthcare Conference on Wednesday, December 10 at 3:55 PM Eastern Time. The conference will take place at the Crowne Plaza Hotel in New York City.

    Comment?

  8. Specialty Enzymes Market - Global Industry Growth, Size, Share,...Read the original story w/Photo

    Thursday Dec 4 | PRWeb

    Latest Report Global Specialty Enzymes Market Analysis Size And Segment Forecasts To 2020 available at GrandViewResearch database. View full report - Positive outlook on global pharmaceutical industry is expected to remain a key driving factor for global specialty enzymes market.

    Comment?

  9. The Zacks Analyst Blog Highlights:BioMarin, Prosensa, Five Prime...Read the original story

    Friday Nov 28 | Sys-Con Media

    Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the BioMarin , Prosensa , Five Prime Therapeutics , AbbVie , Amgen , Biogen and Vertex .

    Comment?

  10. Bristol-Myers Squibb and Five Prime Therapeutics Collaborate on Development of ImmunomodulatorRead the original story

    Wednesday Nov 26 | Biopharm

    There are two more companies linking up in the co-development of immunotherapies in oncology: Bristol-Myers Squibb and Five Prime Therapeutics. The two entities have agreed to evaluate the efficacy of BMS' Opdivo in combination with Five Prime's investigational programmed cell death 1 immune checkpoint inhibitor FPA008 for the treatment of six different tumor types.

    Comment?

  11. Five Prime Therapeutics, Inc. To Present At The 26th Annual Piper Jaffray Healthcare ConferenceRead the original story

    Tuesday Nov 25 | BioSpace

    Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced that Lewis T. "Rusty" Williams, M.D., Ph.D., President and Chief Executive Officer of Five Prime, will present at the 26th Annual Piper Jaffray Healthcare Conference on Wednesday, December 3 at 12:30 PM Eastern Time. The conference will take place at the Palace Hotel in New York City.

    Comment?

  12. BMS and Five Prime Therapeutics to Evaluate Investigational...Read the original story w/Photo

    Monday Nov 24 | Pharmaceutical Processing

    Bristol-Myers Squibb Company and Five Prime Therapeutics have entered into an exclusive clinical collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of combining Opdivo , Bristol-Myers Squibb's investigational PD-1 immune checkpoint inhibitor, with FPA008, Five Prime's monoclonal antibody that inhibits colony stimulating factor-1 receptor . The Phase 1a/1b study will evaluate the combination of Opdivo and FPA008 as a potential treatment option for patients with non-small cell lung cancer , melanoma, head and neck cancer, pancreatic cancer, colorectal cancer and malignant glioma.

    Comment?

  13. BMS, Five Prime Enter Combo Therapy Clinical PactRead the original story w/Photo

    Monday Nov 24 | Contract Pharma Breaking News

    Bristol-Myers Squibb and Five Prime Therapeutics have entered an exclusive clinical collaboration to evaluate the safety and efficacy of BMS' investigational immune checkpoint inhibitor Opdivo with FPA008, Five Prime's monoclonal antibody that inhibits colony stimulating factor-1 receptor . The Phase Ia/Ib study will evaluate the combination as a potential treatment for patients with non-small cell lung cancer , melanoma, head and neck cancer, pancreatic cancer, colorectal cancer and malignant glioma.

    Comment?

  14. Bristol-Myers Squibb Company And Five Prime Therapeutics, Inc....Read the original story

    Sunday Nov 23 | BioSpace

    Bristol-Myers Squibb and Five Prime Therapeutics Announce Exclusive Clinical Collaboration to Evaluate the Combination of Investigational Immunotherapies Opdivo and FPA008 in Six Tumor Types NEW YORK & SOUTH SAN FRANCISCO, Calif.-- --Bristol-Myers Squibb Company and Five Prime Therapeutics, Inc. today announced that they have entered into an exclusive clinical collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of combining Opdivo , Bristol-Myers Squibb's investigational PD-1 immune checkpoint inhibitor, with FPA008, Five Prime's monoclonal antibody that inhibits colony stimulating factor-1 receptor .

    Comment?

  15. Monday Sector Leaders: Music & Electronics Stores, DrugsRead the original story w/Photo

    Monday Nov 24 | Forbes.com

    ... up on the day by about 1.7% as a group, led by Prosensa Holding (RNA), trading up by about 61.3% and Five Prime Therapeutics (FPRX), trading higher by about 17% on Monday.

    Comment?

  16. Bristol-Myers Squibb and Five Prime Therapeutics Announce Exclusive...Read the original story

    Monday Nov 24 | Freshnews

    Bristol-Myers Squibb and Five Prime Therapeutics Announce Exclusive Clinical Collaboration to Evaluate the Combination of Investigational Immunotherapies Opdivo and FPA008 in Six Tumor Typ NEW YORK & SOUTH SAN FRANCISCO, Calif. -- -- Bristol-Myers Squibb Company and Five Prime Therapeutics, Inc. today announced that they have entered into an exclusive clinical collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of combining Opdivo , Bristol-Myers Squibb's investigational PD-1 immune checkpoint inhibitor, with FPA008, Five Prime's monoclonal antibody that inhibits colony stimulating factor-1 receptor .

    Comment?

  17. Five Prime Therapeutics (FPRX) Upgraded From Sell to HoldRead the original story w/Photo

    Tuesday Nov 18 | TheStreet.com

    TheStreet Ratings Team has this to say about their recommendation: "We rate FIVE PRIME THERAPEUTICS INC a HOLD. The primary factors that have impacted our rating are mixed - some indicating strength, some showing weaknesses, with little evidence to justify the expectation of either a positive or negative performance for this stock relative to most other stocks.

    Comment?

  18. Five Prime Therapeutics, Inc. Initiates Dosing Of Rheumatoid...Read the original story

    Nov 17, 2014 | BioSpace

    Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced that the company has initiated dosing of rheumatoid arthritis patients in its Phase 1 clinical trial of FPA008, a monoclonal antibody that inhibits colony stimulating factor-1 receptor . FPA008 is being developed as a potential treatment for RA and solid tumors.

    Comment?

  19. Five Prime Therapeutics Initiates Dosing of Rheumatoid Arthritis...Read the original story w/Photo

    Nov 17, 2014 | GlobeNewswire

    Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced that the company has initiated dosing of rheumatoid arthritis patients in its Phase 1 clinical trial of FPA008, a monoclonal antibody that inhibits colony stimulating factor-1 receptor . FPA008 is being developed as a potential treatment for RA and solid tumors.

    Comment?

  20. Five Prime Therapeutics, Inc. To Present Data From Healthy Volunteer...Read the original story

    Nov 14, 2014 | BioSpace

    Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, announced that it will present results from the healthy volunteer cohorts in its Phase 1 clinical trial of FPA008, a monoclonal antibody that inhibits colony stimulating factor-1 receptor . The results will be featured in a poster presentation titled "A Phase 1 Study of FPA008, an Anti-Colony Stimulating Factor 1 Receptor Antibody in Healthy Volunteers and Subjects with Rheumatoid Arthritis : Preliminary Results" at the 2014 American College of Rheumatology and the Association of Rheumatology Health Professionals Annual Scientific Meeting.

    Comment?